Meriden’s Protein Sciences said it has received a license from federal drug regulators to manufacture its influenza vaccine at its facility in Pearl River, N.Y.
Acquired from Pfizer in late 2012, the facility has four times the manufacturing capacity as Protein’s Meriden plant, according to the company, which said it will continue to make Flublok in Connecticut.
It will ramp up production of Flublok starting this year.
Federal money helped to pay for New York facility, the company said.
In 2009, the Department of Health and Human Services awarded a $34.5 million contract to the company to develop its vaccine, which was approved in early 2013.
While common flu vaccines are grown in chicken eggs, Protein Sciences uses a faster method, which HHS officials said would be of use if a fast-spreading epidemic arose.
